

1 ***Infectious Complications in Philadelphia-Negative Adolescent and***
2 ***Young Adult Acute Lymphoblastic Leukemia Patients in the Era of***
3 ***Pediatric-Inspired Regimen***

4
5 Phouthasin Vongngakesone^{1,2}, Piangrawee Niprapan¹, Sirichai Srichairatanakool¹, Nonthakorn
6 Hantrakun¹, Teerachat Punnachet¹, Sasinee Hantrakool¹, Pokpong Piriyaikhuntorn¹, Chatree
7 Chai-Adisaksopha¹, Ekarat Rattarittamrong¹, Adisak Tantiworawit¹, Lalita Norasetthada¹,
8 Thanawat Rattanathammethee^{1*}

9
10 ¹Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai
11 University, Chiang Mai, Thailand

12 ²Department of Internal Medicine, Setthathirath Hospital, Vientiane, Lao PDR

13
14 *Corresponding author

15 Email: thanawat.r@cmu.ac.th (TR)

16
17
18
19
20
21

22 Abstract

23 **Introduction:** Pediatric acute lymphoblastic leukemia (ALL) has cure rates exceeding 90%, while
24 adult ALL has a 3-year survival rate of only 40–50%. Adolescents and young adults (AYAs) face
25 unique challenges due to age-related factors and high-risk disease features. Although pediatric-
26 inspired regimens improve survival, intensive chemotherapy increases susceptibility to severe
27 infections.

28 **Methods:** A retrospective analysis was conducted on AYA-ALL patients treated at Chiang Mai
29 University Hospital from 1 January 2007 to 31 December 2023. Patients were classified into
30 pediatric-inspired (TPOG) or adult regimens (Hyper-CVAD or GMALL). Infections were
31 categorized as clinically documented infections (CDI) or microbiologically documented
32 infections (MDI). Multivariate logistic regression was used to identify infection risk factors.

33 **Results:** Among 94 patients (62.8% male; median age 22.9 years), 56.4% received TPOG and
34 43.6% received adult regimens. Infectious complications occurred in 79.8% of patients, with
35 higher rates in the adult regimen group (90.2% vs. 71.7%, $p = 0.03$). CDI was more frequent in
36 the adult group (73.4% vs. 52.8%, $p = 0.04$), while fungal infections were more common in the
37 TPOG group (26.4% vs. 9.8%, $p = 0.04$). Adult regimens significantly increased infection risk
38 (OR 3.55; 95% CI 1.02–12.36, $p = 0.04$). Infection rates peaked during induction (47.8%) and
39 consolidation (51.8%). During induction, MDI was lower in the adult group (21% vs. 79%, $p =$
40 0.01), while CDI was higher during consolidation (69% vs. 30%, $p < 0.01$). Gram-negative
41 bacteria were the most common pathogens (85%), particularly *E. coli* (27%) and *Salmonella* spp.
42 (21%). Fungal infections affected 19.1% of patients, with invasive pulmonary aspergillosis being
43 the most common (11.7%).

44 **Conclusion:** AYA-ALL patients are highly susceptible to infections, especially those receiving
45 adult regimens. Fungal infections were notably more common in patients on the TPOG regimen.
46 Strengthening infection prevention and providing early treatment are vital for improving patient
47 outcomes.

48 **Keywords:** Acute lymphoblastic leukemia, Adolescents and young adults, Infectious
49 complications, Pediatric-inspired regimen, microbiologically documented infections

50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69

70 **Introduction**

71 Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer but is relatively rare in
72 adults, with an incidence of 1.7 cases per 100,000 annually in the total U.S. population [1]. Over
73 the past few decades, the prognosis for pediatric ALL has significantly improved, with cure rates
74 exceeding 90% using standard intensive multi-agent chemotherapy protocols [2, 3]. However,
75 adult ALL remains associated with poorer outcomes, with only 40-50% survival at three years [4].
76 This survival gap is likely due to differences in disease biology, treatment response, and patient-
77 related factors.

78 Adolescents and young adults (AYAs), aged 15 to 39 years, face distinct treatment challenges due
79 to their transitional physiology and a higher prevalence of high-risk disease features, resulting in
80 event-free survival rates of 30-45% [5-7]. The presence of specific genetic factors, diversity within
81 this age range, and different treatment protocols may contribute to the lower survival rates
82 observed in adult ALL patients.

83 Multiple retrospective and prospective studies have demonstrated that pediatric-inspired regimens
84 significantly improve survival outcomes in AYAs compared to standard adult regimens [8-10].
85 Despite improved survival, infections remain a significant cause of morbidity and mortality,
86 particularly during induction therapy, affecting over 30% of patients. Bacterial infections
87 accounted for nearly 70% of infection-related deaths, while fungal infections accounted for about
88 20% [11].

89 In Thailand, a study involving 107 ALL patients (67.3% received adult regimens and 32.7%
90 received pediatric-inspired regimens) found that patients treated with pediatric-inspired protocols
91 had better two-year disease-free survival (47.1% vs. 24.7%, hazard ratio [HR] 1.73, 95% CI 1.22–

92 3.03) and overall survival (50.8% vs. 31.2%, HR 1.52, 95% CI 0.83–2.78) compared to those
93 treated with adult regimens [12]. Similarly, a multi-centre prospective study showed that AYAs
94 had significantly higher two-year event-free survival compared to adults with ALL (45.5% vs
95 26.2%; $P < 0.019$) [13].

96 Despite evidence supporting pediatric-inspired regimens, the infection risks and associated factors
97 in AYAs with ALL remain understudied, particularly when comparing pediatric-inspired and adult
98 regimens in Thailand.

99

100 **Methods**

101 **Study design and Patients**

102 This retrospective cohort study included newly diagnosed adolescent and young adult patients with
103 acute lymphoblastic leukemia (AYA-ALL), aged 15-40 years, treated at Chiang Mai University
104 Hospital between 1 January 2007 and 31 December 2023. The diagnosis was confirmed according
105 to the 2016 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues [14]. This
106 study followed the Declaration of Helsinki and the International Conference on Harmonization
107 Guidelines for Good Clinical Practice. The institutional ethical review board of the Faculty of
108 Medicine, Chiang Mai University, Thailand, approved the study (study code: MED-2566-0630).
109 Informed consent was waived due to the retrospective design and anonymized data collection.

110 Patients received induction chemotherapy using either a pediatric-inspired regimen (a modified
111 Thai Pediatric Oncology Group [TPOG] protocol) [12, 15], a dosage and intensity-adjusted
112 version of the Thai national childhood ALL protocol, or adult regimens (Hyper-CVAD or

113 GMALL) [16, 17]. Patients were excluded if they did not receive high-intensity chemotherapy,
114 had Philadelphia chromosome-positive ALL and/or the *BCR::ABL1* fusion gene (detected via
115 polymerase chain reaction), had incomplete clinical records, received induction therapy prior to
116 referral, or had a known HIV infection. All patients received standard antimicrobial prophylaxis
117 with trimethoprim/sulfamethoxazole for *Pneumocystis jirovecii* pneumonia (PJP) and acyclovir
118 for herpes simplex virus (HSV) infections. Due to limited availability of mold-active antifungal
119 agents, fluconazole was used for fungal prophylaxis. However, fluconazole and
120 trimethoprim/sulfamethoxazole were withheld during certain treatment phases to prevent drug
121 interactions. Granulocyte colony-stimulating factor (G-CSF) was routinely administered during
122 induction and consolidation phases to reduce neutropenia-related infection risk. Notably, specific
123 data on antimicrobial prophylaxis regimens for bacterial, fungal, and viral infections were not
124 analyzed in this study.

125 **Data collection and outcomes**

126 Clinical data were retrospectively collected from electronic medical records with de-identified
127 patients' data, potential bias from missing data. Data included baseline demographics, laboratory
128 results, infectious events, and treatment outcomes. Infectious complications during all
129 chemotherapy phases (induction, consolidation, and maintenance) were analyzed.

130 The primary outcome was the prevalence of infectious complications among AYA-ALL patients.
131 The secondary outcomes were to identify associated risk factors for infectious complications and
132 compare the infectious complications rate between patients receiving pediatric-inspired (TPOG)
133 and adult regimens (Hyper-CVAD or GMALL).

134

135 **Definitions of infectious complications**

136 Infectious complications were categorized as follows:

- 137 • **Clinically Documented Infection (CDI):** Clinical signs and symptoms of infection
138 without an identifiable pathogen.
- 139 • **Microbiologically Documented Infection (MDI):** Isolation of a pathogen from blood
140 cultures or other infection sites.

141 Fever was defined as a body temperature $>38.3^{\circ}\text{C}$ or a temperature $>38^{\circ}\text{C}$ persisting for at least 1
142 hour. Febrile neutropenia was defined as fever with an absolute neutrophil count (ANC) $< 500/\mu\text{L}$
143 [18].

144 **Sample size and statistical analysis**

145 Based on previous studies [9, 10], an infection prevalence of 50% was assumed in AYA-ALL
146 patients. The required sample size was 97 patients, with a margin of error of 10% [19]. Continuous
147 variables were reported as mean with standard deviation (SD) or median with interquartile range
148 (IQR), depending on data distribution. Categorical variables were expressed as counts and
149 percentages. Group comparisons for categorical data were performed using the chi-square test or
150 Fisher's exact test. Continuous variables were compared using the Student's *t*-test or Mann-
151 Whitney *U* test, as appropriate. Variables with a *p*-value < 0.1 in univariate analysis were entered
152 into a backward stepwise multivariate logistic regression model to identify independent risk factors
153 for infections. Results were reported as odds ratios (OR) and 95% confidence intervals (CI).
154 Statistical significance was set at *p*-value < 0.05 . Patients with missing data were excluded. All

155 analyzes were performed using Microsoft Excel 2013 and STATA Version 17 (StataCorp, TX,
156 USA) software.

157

158 **Results**

159 **Demographic and clinical characteristics**

160 A total of 124 newly diagnosed Philadelphia-negative ALL patients at Chiang Mai University
161 Hospital between 1 January 2007 and 31 December 2023 were retrospectively reviewed, 30
162 patients were excluded, and 94 AYA-ALL patients were recruited (**Fig 1**). The majority were male
163 (62.8%, n = 59), with a median age of 22.9 years (IQR 15-39.8). B-ALL was the most common
164 subtype (58.8%). Of these, 56.4% (n = 53) received pediatric-inspired TPOG regimen, while
165 43.6% (n = 41) received adult regimens (24 on Hyper-CVAD and 17 on GMALL). Overall, the
166 median follow-up was 14.3 months (IQR 7.5-30.9). Relapse or refractory disease occurred in
167 55.3% of patients, with a significantly higher rate in the adult regimen group compared to the
168 TPOG group (68.3 % vs. 45.3, $p = 0.02$). Only four patients (4.3%) underwent allogeneic stem cell
169 transplantation (AlloSCT). Baseline characteristics were summarized in **Table 1**.

170

171 **Fig 1. Flow diagram demonstrated the recruitment alongside of inclusion and exclusion**
172 **criteria**

173

174

175 **Table 1. Demographic and clinical characteristics of AYA-ALL patients**

Variables	All patients (n = 94)	TPOG (n = 53)	Adult regimen (n = 41)	p-value
Age, years	22.9 (15-39.8)	23.8(15-39.2)	21.7 (15-39.8)	0.63
Male, n (%)	59 (62.8)	36 (67.9)	23 (56.1)	0.24
ALL subtype, n (%)				0.31
B-ALL	55 (58.5)	31 (58.5)	24 (58.5)	
T-ALL	37 (39.4)	22 (41.5)	15 (36.6)	
N/A	2 (2.1)	0	2 (4.9)	
Hemoglobin, g/dL	9.5 (7.5-11.4)	9.5 (7.4-11.7)	9.1 (7.5-11.2)	0.60
WBC, / μ L	16600 (4500-47500)	23000 (5200-51400)	14170 (3570-39400)	0.40
Platelet, / μ L	75900 (32000-145000)	84000 (33000-158000)	65000 (32000-139000)	0.73
Peripheral blood blasts, %	49.5 (4-83)	48 (4.7-85)	50 (3-82)	0.82
Bone marrow blasts, %	90 (80-90)	90(80-90)	90(80-90)	0.12
Induction death, n (%)	4 (4.2)	2 (3.8)	2 (4.8)	1
Proceed to consolidation phase, n (%)	81 (86.1)	44 (83.0)	37 (90.2)	0.31
Duration of consolidation, days	223 (93-313)	261.5 (109.5- 398.5)	199 (66-245)	<0.01
Proceed to maintenance phase, n (%)	31 (32.9)	18 (33.9)	13 (31.7)	0.81
Duration of maintenance, days	721 (301-770)	731 (385-862)	516 (147-744)	0.16
Completed maintenance phase, n (%)	16 (51.6)	10 (55.5)	6 (46.1)	0.72
Relapse/Refractory, n (%)	52 (55.3)	24 (45.3)	28 (68.3)	0.02
Allogeneic SCT, n (%)	4 (4.3)	3 (5.7)	1 (2.4)	0.62

As the continuous data in this study did not follow a normal distribution, all data were reported as medians with interquartile ranges (IQR). WBC: white blood cell count, SCT: stem cell transplantation

176

177

178

179

180

181 Infectious outcomes

182 Infectious complications were reported in 79.8% (n = 75) of patients. Clinically documented
183 infections (CDI) occurred in 61.7% (n = 58), and microbiologically documented infections (MDI)
184 in 55.3% (n = 52). Bacterial infections were the most common (44.6%, n = 42), followed by fungal
185 infections (19.1%, n = 18).

186 Patients on adult regimens experienced significantly more infectious complications than those on
187 the TPOG regimen (90.2% vs. 71.7%, $p = 0.03$), with higher CDI rates (73.4% vs. 52.8%, $p =$
188 0.04). Conversely, fungal infections were more frequent in the TPOG group (26.4% vs. 9.8%, $p =$
189 0.04) (**Table 2**).

190 **Table 2. Infectious complications among AYA-ALL patients based on treatment regimens**

Variables	All patients (n=94)	TPOG (n=53)	Adult regimen (n=41)	<i>p</i> -value
Overall infection, n (%)	75 (79.8)	38 (71.7)	37 (90.2)	0.03
CDI, n (%)	58 (61.7)	28 (52.8)	30 (73.2)	0.04
MDI, n (%)	52 (55.3)	28 (52.8)	24 (58.5)	0.58
Bacterial infection, n (%)	42 (44.6)	22 (41.5)	20 (48.8)	0.48
Fungus infection, n (%)	18 (19.1)	14 (26.4)	4 (9.8)	0.04

CDI: clinically documented infection, MDI: microbiologically documented infection

191
192 Infection rates peaked during induction (47.8%) and consolidation (51.8%). During consolidation,
193 infections were significantly higher in the adult regimen group compared to the TPOG group
194 (64.9% vs. 40.9%, $p = 0.03$) (**Fig 2**). MDI was most frequent in the TPOG group during induction
195 (79% vs. 21%, $p = 0.01$), whereas CDI was more common in the adult regimen group during the
196 consolidation (69% vs. 30%, $p < 0.01$) (**S1 Table**). Details of CDI based on treatment group and
197 phase of treatment were provided (**S2 Table**).

198 **Fig 2. Number of infection based on treatment regimens and treatment phases**

199

200 **S1 Table. Number and types of infectious episodes (CDI and MDI) based on treatment**

201 **regimens and treatment phases**

202

203 **S2 Table. Clinically documented infection (CDI) based on treatment regimens and**

204 **treatment phases**

205

206 The most common infection sites for MDI were the bloodstream (40%), lung (24%) and the

207 genitourinary tract (16%) (**S3 Table**). Bacterial infections were the most prevalent (73%),

208 followed by fungal (24%) and viral (3%) infections. Gram-negative bacteria dominated (85%)

209 among bacterial pathogens, with *E. coli* (27%), *Salmonella spp.* (21%), and *Klebsiella spp.* (19%)

210 being the most prevalent. *Aspergillus spp.* was the most common fungal pathogen (**S4 Table and**

211 **S5 Table**). Induction-related mortality was 4.2% (n = 4), with septicemia causing death in 2

212 patients and hemorrhagic complications in 2 patients.

213 **S3 Table. Sites of microbiologically documented infection (MDI) based on treatment**

214 **regimens and treatment phases**

215 **S4 Table. Isolated pathogens of MDI in TPOG regimen group**

216 **S5 Table. Isolated pathogens of MDI in adult regimen group**

217

218

219 Risk factors for infectious complications

220 Multivariate logistic regression identified treatment with an adult regimen as a significant risk
 221 factor for infectious complications among AYA-ALL patients (OR 3.55, 95% CI 1.02–12.36, $p =$
 222 0.04) (**Table 3**). For MDI, female sex (OR 3.88, 95% CI 1.41–10.68, $p < 0.01$) and platelet counts
 223 below 75,000 / μ L (OR 3.41, 95% CI 1.33–8.74, $p = 0.01$) were independently associated with a
 224 higher risk. In contrast, patients younger than 23 years (OR 0.33, 95% CI 0.12–0.85, $p = 0.02$) and
 225 those receiving only first-line treatment (OR 0.36, 95% CI 0.13–0.93, $p = 0.03$) had a significantly
 226 lower risk of MDI (**S6 Table**).

227

228 **Table 3. Univariate and multivariate analyses of risk factor for infectious complications**

Variables		Univariate			Multivariate		
		Infection (n=75)	Non infection (n=19)	p -value	Odds ratio	95% CI	p -value
Treatment regimens	Adults	37 (90.2)	4 (9.8)	0.026	3.55	1.02-12.36	0.04
	TPOG	38 (71.7)	15 (28.3)				
Sex	Female	30 (85.7)	5 (14.3)	0.2			
	male	45 (76.3)	14 (23.7)				
ALL type	B cell	44 (80)	8 (20.5)	0.95			
	others	31 (79.5)	11 (20.0)				
Relapse	yes	44 (84.6)	8 (15.4)	0.19			
	no	31 (73.8)	11 (26.2)				
1 st line of treatment	yes	39 (72.2)	15 (27.8)	0.03	0.4	0.11-1.40	0.155
	no	36 (90)	4 (10)				
Age, years	< 23	37 (78.7)	10 (21.3)	0.79			
	\geq 23	38 (80.8)	9 (19.1)				
WBC, / μ L	<16600	40 (85.1)	7 (14.9)	0.19			

	≥ 16600	35 (74.5)	12 (25.5)				
Hb, g/dL	< 9.5	38 (80.9)	9 (19.1)	0.79			
	≥ 9.5	37 (78.7)	10 (21.3)				
Platelet, / μ L	<75000	39 (84.8)	7 (15.2)	0.23			
	≥ 75000	36 (75.0)	12 (25.0)				
PB blasts, %	<50%	42 (89.4)	5 (10.6)	0.02	3.41	1.05-11.04	0.04
	$\geq 50\%$	33 (70.2)	14(29.8)				
BM blasts, %	<90%	34 (79.0)	9 (20.9)	0.87			
	$\geq 90\%$	41 (80.4)	10 (19.6)				

WBC: white blood cell count, Hb: hemoglobin, PB: peripheral blood, BM: bone marrow

229

230 **S6 Table. Univariate and multivariate analyses of risk factor for MDI**

231 **Discussion**

232 This study demonstrated a high incidence of infectious complications in AYA-ALL patients, with
 233 79.8% experiencing infections. Clinically documented infections (CDI) occurred in 61.7% of
 234 patients, and microbiologically documented infections (MDI) in 55.3%. These rates are
 235 comparable to studies from Taiwan and Mexico, which reported infection rates of approximately
 236 87% in ALL patients receiving intensive chemotherapy [20, 21]. Similarly, an Italian study
 237 highlighted infectious complications as a leading cause of morbidity in AYA-ALL patients,
 238 underscoring the importance of infection prevention strategies [22].

239 **Phase-specific infection risk**

240 Infection rates were highest during the induction (47.8%) and consolidation (51.8%) phases,
 241 aligning with findings from MD Anderson, which reported infection rates of 22% and 63% during

242 these phases, respectively [9]. The increased risk during induction is likely due to the intensive
243 chemotherapy and high-dose steroids, causing severe myelosuppression and immune suppression.
244 During consolidation, cumulative immunosuppression further elevates infection risk. Differences
245 in regimen intensity between TPOG and adult protocols may explain the observed variation in
246 infection rates, highlighting the need for phase-specific supportive care.

247 **Fungal infection in the TPOG group**

248 Fungal infections were more frequent in patients receiving the TPOG regimen (26.4%) compared
249 to those on adult regimens (9.8%), consistent with findings from Mexico, where 20% of ALL
250 patients developed fungal infections [21]. This increased risk in the TPOG group may result from
251 higher steroid doses and longer chemotherapy durations, which prolong immunosuppression and
252 impair both humoral and cellular immunity. Additionally, fluconazole was used for antifungal
253 prophylaxis due to limited access to mold-active agents at our center, potentially contributing to
254 the higher rates of *Aspergillus* infections. In contrast, studies from Saudi Arabia reported lower
255 fungal infection rates with micafungin or anidulafungin prophylaxis [23]. Environmental factors,
256 particularly in tropical climates, may also increase fungal exposure [24].

257 **Bacterial infections predominate in adult regimens**

258 Gram-negative bacteria were the most common pathogens (85%), with *E. coli* (27%)
259 and *Salmonella* spp. (21%) being the most prevalent. These findings align with studies from Italy,
260 where gram-negative organisms were predominant in leukemia patients [25]. Patients on adult
261 regimens experienced significantly more bacterial infections, likely due to prolonged and severe
262 neutropenia associated with these protocols.

263 **Risk factors for infection**

264 Multivariate analysis identified treatment with adult regimens as a significant risk factor for overall
265 infections (OR 3.55; $p = 0.04$). Female gender (OR 3.88; $p < 0.01$) and platelet counts below
266 75,000/ μL (OR 3.41; $p = 0.01$) were independent risk factors for MDI. Conversely, younger
267 patients (<23 years) and those receiving first-line treatment had a lower infection risk. The higher
268 infection rate in females may be due to a higher incidence of urinary tract infections, as reported
269 in other studies [20].

270 **Clinical implications**

271 These findings emphasize the need for tailored infection prevention strategies based on treatment
272 regimen and phase. For patients receiving pediatric-inspired regimens, particularly TPOG, the use
273 of mold-active antifungal prophylaxis should be considered. Patients on adult regimens may
274 benefit from more aggressive bacterial infection prevention and early intervention during
275 neutropenic episodes. Environmental and regional factors must also be considered when designing
276 infection control protocols.

277 **Study limitations**

278 This study has several limitations that should be considered when interpreting the findings. Its
279 retrospective design may introduce selection bias, and incomplete or inconsistent medical records
280 could affect data accuracy. The relatively small sample size and single-center setting limit the
281 generalizability of the results to broader populations and other healthcare settings. Additionally,
282 the study did not analyze antimicrobial resistance patterns, which could impact the interpretation
283 of infection outcomes. Variations in antimicrobial prophylaxis regimens for bacterial, fungal, and

284 viral infections were also not fully assessed, potentially influencing infection rates. These
285 limitations highlight the need for larger, multi-center prospective studies to validate these findings
286 and optimize infection prevention strategies in AYA-ALL patients.

287

288 **Conclusions**

289 Our study highlights the high burden of infectious complications in AYA-ALL patients,
290 particularly those receiving adult chemotherapy regimens. Fungal infections were notably more
291 common in patients treated with pediatric-inspired regimens, likely due to prolonged steroid use
292 and insufficient mold-active antifungal prophylaxis. These findings underscore the need for
293 targeted infection prevention and early intervention strategies to improve outcomes in this
294 vulnerable population.

295

296 **Supporting information**

297 **S1-6 File.** The table S1 to S6 (S1-6_Table.docx)

298 **S1 Table.** Number and types of infectious episodes (CDI and MDI) based on treatment regimens
299 and treatment phases

300 **S2 Table.** Clinically documented infection (CDI) based on treatment regimens and treatment
301 phases

302 **S3 Table.** Sites of microbiologically documented infection (MDI) based on treatment regimens
303 and treatment phases

304 **S4 Table.** Isolated pathogens of MDI in TPOG regimen group

305 **S5 Table.** Isolated pathogens of MDI in adult regimen group

306 **S6 Table.** Univariate and multivariate analyses of risk factor for MDI

307

308 **Acknowledgements**

309 I would like to express my sincere gratitude to all the staff at the Division of Hematology,
310 Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, for their invaluable
311 support and dedication to patient care throughout this study.

312 **Conflict of Interest Statement**

313 The author(s) have declared that no potential conflicts of interest relevant to this article

314 **Funding Sources**

315 There was no funding in this study.

316 **Ethics Statement**

317 The study was conducted in accordance with the International Conference on Harmonization for
318 Good Clinical Practice guidelines and the 1964 Declaration of Helsinki. The study was approved
319 by the the institutional ethical review board of the Faculty of Medicine, Chiang Mai University,
320 Thailand (study code: MED-2566-0630). Informed consent was waived due to the retrospective
321 design and anonymized data collection.

322

323 **Author's contributions:**

324 Conceptualization: Thanawat Rattanathamthee

325 Methodology: Thanawat Rattanathamthee

326 Data curation: Thanawat Rattanathamthee, Phoutthasin Vongngakesone

327 Formal analysis: Thanawat Rattanathamthee, Phoutthasin Vongngakesone

328 Investigation: Thanawat Rattanathamthee, Phoutthasin Vongngakesone

329 Writing-Original draft: Thanawat Rattanathamthee, Phoutthasin Vongngakesone

330 Writing- review and editing: All authors

331

332 **Data Availability Statement**

333 The datasets generated during and/or analyzed in the current study, containing potentially
334 sensitive patient information and de-identified patient data, are available through the research
335 administration section of the Faculty of Medicine at Chiang Mai University, Thailand. (email:
336 researchmed@cmu.ac.th)

337

338

339

340

341

342

343

344

345

346 **References**

- 347 1. Surveillance, Epidemiology, and End Results Program (SEER) Cancer Stat Facts:
348 Leukemia - Acute Lymphocytic leukemia (ALL). National Cancer Institute. Bethesda, MD
349 [Available from: <https://seer.cancer.gov/statfacts/html/aly1.html>]. Accessed 18 January 2025.
- 350 2. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, et al. What
351 determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia
352 treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and
353 Leukemia Group B studies. *Blood*. 2008;112(5):1646-54.
- 354 3. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. *N Engl J Med*.
355 2015;373(16):1541-52.
- 356 4. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of
357 treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. *J*
358 *Clin Oncol*. 2000;18(3):547-61.
- 359 5. Curran E, Stock W. How I treat acute lymphoblastic leukemia in older adolescents and
360 young adults. *Blood*. 2015;125(24):3702-10.
- 361 6. Roberts KG. Genetics and prognosis of ALL in children vs adults. *Hematology Am Soc*
362 *Hematol Educ Program*. 2018;2018(1):137-45.
- 363 7. Tran TH, Tasian SK. How I treat Philadelphia chromosome-like acute lymphoblastic
364 leukemia in children, adolescents, and young adults. *Blood*. 2025;145(1):20-34.
- 365 8. Hallbook H, Gustafsson G, Smedmyr B, Soderhall S, Heyman M, Swedish Adult Acute
366 Lymphocytic Leukemia G, et al. Treatment outcome in young adults and children >10 years of

- 367 age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and
368 an adult protocol. *Cancer*. 2006;107(7):1551-61.
- 369 9. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, et al. Final
370 results of a single institution experience with a pediatric-based regimen, the augmented Berlin-
371 Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and
372 comparison to the hyper-CVAD regimen. *Am J Hematol*. 2016;91(8):819-23.
- 373 10. Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, et al. A pediatric
374 regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of
375 CALGB 10403. *Blood*. 2019;133(14):1548-59.
- 376 11. O'Connor D, Bate J, Wade R, Clack R, Dhir S, Hough R, et al. Infection-related mortality
377 in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.
378 *Blood*. 2014;124(7):1056-61.
- 379 12. Tantiworawit A, Rattanathammethee T, Chai-Adisaksopha C, Rattarittamrong E,
380 Norasetthada L. Outcomes of adult acute lymphoblastic leukemia in the era of pediatric-inspired
381 regimens: a single-center experience. *Int J Hematol*. 2019;110(3):295-305.
- 382 13. Limvorapitak W, Owattanapanich W, Utchariyaprasit E, Niparuck P, Puavilai T,
383 Tantiworawit A, et al. Better survivals in adolescent and Young adults, compared to adults with
384 acute lymphoblastic leukemia - A multicenter prospective registry in Thai population. *Leuk Res*.
385 2019;87:106235.
- 386 14. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016
387 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
388 *Blood*. 2016;127(20):2391-405.

- 389 15. Seksarn P, Wiangnon S, Veerakul G, Chotsampancharoen T, Kanjanapongkul S,
390 Chainansamit SO. Outcome of Childhood Acute Lymphoblastic Leukemia Treated Using the Thai
391 National Protocols. *Asian Pac J Cancer Prev*. 2015;16(11):4609-14.
- 392 16. Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al. Leading
393 prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic
394 leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase
395 chain reaction analysis. *Blood*. 2002;99(5):1536-43.
- 396 17. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up
397 results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone
398 (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. *Cancer*.
399 2004;101(12):2788-801.
- 400 18. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice
401 guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by
402 the infectious diseases society of america. *Clin Infect Dis*. 2011;52(4):e56-93.
- 403 19. Naing L, Nordin RB, Abdul Rahman H, Naing YT. Sample size calculation for prevalence
404 studies using Scalex and ScalaR calculators. *BMC Med Res Methodol*. 2022;22(1):209.
- 405 20. Li MJ, Chang HH, Yang YL, Lu MY, Shao PL, Fu CM, et al. Infectious complications in
406 children with acute lymphoblastic leukemia treated with the Taiwan Pediatric Oncology Group
407 protocol: A 16-year tertiary single-institution experience. *Pediatr Blood Cancer*. 2017;64(10).
- 408 21. Inclan-Alarcon SI, Riviello-Goya S, Teran-De-la-Sancha K, Fierro-Angulo OM, Acosta-
409 Medina AA, Demichelis-Gomez R, et al. Induction-related mortality in adolescents and young

- 410 adults with acute lymphoblastic leukemia in a resource-limited setting: do treatment-related
411 complications create more impact than disease biology? *Blood Res.* 2022;57(1):29-33.
- 412 22. Zappasodi P, Calabretta L, Lazzarotto D, Cerrano M, Fracchiolla N, Papayannidis C, et al.
413 Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic
414 Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol. *Blood.*
415 2023;142(Supplement 1):5877-.
- 416 23. Salama H, Eldadah S, Omer MH, Alhejazi A, Bin Dayil L, Almozaini A, et al. Comparison
417 of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults
418 with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis.
419 *Leuk Res.* 2023;130:107316.
- 420 24. Tang JL, Kung HC, Lei WC, Yao M, Wu UI, Hsu SC, et al. High Incidences of Invasive
421 Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy
422 without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan. *PLoS*
423 *One.* 2015;10(6):e0128410.
- 424 25. Offidani M, Corvatta L, Malerba L, Marconi M, Leoni P. Infectious complications in adult
425 acute lymphoblastic leukemia (ALL): experience at one single center. *Leuk Lymphoma.*
426 2004;45(8):1617-21.




Figure2

124 newly diagnosed Philadelphia-negative ALL patients
(1 January 2007 to 31 December 2023)

Exclusion criteria

- 25 age at diagnosis > 40 years
- 2 not receiving chemotherapy
- 3 missing data

94 Philadelphia-negative AYA-ALL patients
met **inclusion criteria**

Figure 1